| Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study G Cavalli, G De Luca, C Campochiaro, E Della-Torre, M Ripa, D Canetti, ... The Lancet Rheumatology 2 (6), e325-e331, 2020 | 1065 | 2020 |
| Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease EL Diamond, L Dagna, DM Hyman, G Cavalli, F Janku, J Estrada-Veras, ... Blood, The Journal of the American Society of Hematology 124 (4), 483-492, 2014 | 601 | 2014 |
| Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... Nature medicine 27 (10), 1752-1760, 2021 | 491 | 2021 |
| Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study C Campochiaro, E Della-Torre, G Cavalli, G De Luca, M Ripa, N Boffini, ... European journal of internal medicine 76, 43-49, 2020 | 458 | 2020 |
| Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors M Ripa, L Galli, A Poli, C Oltolini, V Spagnuolo, A Mastrangelo, C Muccini, ... Clinical Microbiology and Infection 27 (3), 451-457, 2021 | 382 | 2021 |
| Suppression of inflammation and acquired immunity by IL‐37 G Cavalli, CA Dinarello Immunological reviews 281 (1), 179-190, 2018 | 298 | 2018 |
| Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi, P Wung, N Patel, ... The Lancet Respiratory Medicine 9 (5), 522-532, 2021 | 275 | 2021 |
| Anakinra therapy for non-cancer inflammatory diseases G Cavalli, CA Dinarello Frontiers in pharmacology 9, 1157, 2018 | 272 | 2018 |
| Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study E Della-Torre, C Campochiaro, G Cavalli, G De Luca, A Napolitano, ... Annals of the rheumatic diseases 79 (10), 1277-1285, 2020 | 258 | 2020 |
| Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases G Cavalli, S Colafrancesco, G Emmi, M Imazio, G Lopalco, MC Maggio, ... Autoimmunity reviews 20 (3), 102763, 2021 | 234 | 2021 |
| GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study G De Luca, G Cavalli, C Campochiaro, E Della-Torre, P Angelillo, ... The Lancet Rheumatology 2 (8), e465-e473, 2020 | 228 | 2020 |
| Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies G Cavalli, CA Dinarello Rheumatology 54 (12), 2134-2144, 2015 | 213 | 2015 |
| The multifaceted clinical presentations and manifestations of Erdheim–Chester disease: comprehensive review of the literature and of 10 new cases G Cavalli, B Guglielmi, A Berti, C Campochiaro, MG Sabbadini, L Dagna Annals of the rheumatic diseases 72 (10), 1691-1695, 2013 | 213 | 2013 |
| Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study G Cavalli, A Larcher, A Tomelleri, C Campochiaro, E Della-Torre, ... The Lancet Rheumatology 3 (4), e253-e261, 2021 | 172 | 2021 |
| Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis E Kyriazopoulou, T Huet, G Cavalli, A Gori, M Kyprianou, P Pickkers, ... The Lancet Rheumatology 3 (10), e690-e697, 2021 | 151 | 2021 |
| Erdheim-chester disease C Campochiaro, A Tomelleri, G Cavalli, A Berti, L Dagna European journal of internal medicine 26 (4), 223-229, 2015 | 150 | 2015 |
| 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases JM Gwinnutt, M Wieczorek, A Balanescu, HA Bischoff-Ferrari, A Boonen, ... Annals of the rheumatic diseases 82 (1), 48-56, 2023 | 139 | 2023 |
| BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease MG Cangi, R Biavasco, G Cavalli, G Grassini, E Dal-Cin, C Campochiaro, ... Annals of the rheumatic diseases 74 (8), 1596-1602, 2015 | 137 | 2015 |
| Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation G Cavalli, M Koenders, V Kalabokis, J Kim, AC Tan, C Garlanda, ... Rheumatology 55 (12), 2220-2229, 2016 | 118 | 2016 |
| Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection Effect of parenteral treatment with SAMe A Castagna, CL Grazie, A Accordini, P Giulidori, G Cavalli, T Bottiglieri, ... Neurology 45 (9), 1678-1683, 1995 | 118 | 1995 |
